Provided by Tiger Trade Technology Pte. Ltd.

Indaptus Therapeutics, Inc.

3.90
-0.6000-13.33%
Post-market: 4.150.2500+6.41%19:56 EDT
Volume:301.08K
Turnover:1.25M
Market Cap:440.70M
PE:-0.23
High:4.60
Open:4.50
Low:3.66
Close:4.50
52wk High:19.91
52wk Low:0.9200
Shares:113.00M
Float Shares:1.18M
Volume Ratio:0.24
T/O Rate:25.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-16.8254
EPS(LYR):-21.5800
ROE:-931.79%
ROA:-286.81%
PB:353.17
PE(LYR):-0.18

Loading ...

Top Premarket Decliners

MT Newswires Live
·
Jun 05

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:47 PM

Reuters
·
Jun 05

Indaptus Therapeutics Q1 net loss narrows as expenses fall

Reuters
·
May 15

Indaptus net loss narrows to $2.5 million in Q1 FY26; R&D expenses drop 82% to $491,134

Reuters
·
May 15

Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 15

Indaptus Therapeutics Q1 EPS USD -0.23

THOMSON REUTERS
·
May 15

Indaptus Therapeutics Inc expected to post a loss of $1.87 a share - Earnings Preview

Reuters
·
May 08

Indaptus amends 8-K to reflect director Johnny Fox Arrowsmith legal name change

Reuters
·
Apr 25

Indaptus Therapeutics director Qinglai Lu files initial beneficial ownership statement

Reuters
·
Apr 21

Indaptus Therapeutics Inc - Appoints Yu Ding as CFO Effective April 1, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 04

Indaptus Therapeutics names Yu Ding CFO after Nir Sassi resignation

Reuters
·
Apr 04

Indaptus Therapeutics files Form 3; Sino Lion Ventures reports beneficial ownership

Reuters
·
Apr 03

Indaptus Therapeutics files Form 3 for CEO Junyi Dai initial beneficial ownership statement

Reuters
·
Apr 03

Indaptus Therapeutics FY2025 annual report published; net loss widens to $21 million

Reuters
·
Mar 27

Indaptus investors group discloses 96.2% beneficial ownership after preferred conversion

Reuters
·
Mar 25

Indaptus Therapeutics FY2025 net loss widens 38.8% to USD 20.85 million

Reuters
·
Mar 18

Indaptus Therapeutics Inc expected to post a loss of $4.36 a share - Earnings Preview

Reuters
·
Mar 06

Indaptus Therapeutics Wins Approval for Reverse Stock Split Authority

Reuters
·
Feb 28

Indaptus Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Jerome D. Jabbour

Reuters
·
Feb 28

Indaptus Therapeutics Director Matthew Charles McMurdo Files Initial Statement of Beneficial Ownership (Form 3)

Reuters
·
Feb 26